Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Daniel J. Booser"'
Autor:
Windy Dean-Colomb, Francisco J. Esteva, Gabriel N. Hortobagyi, Stacy L. Moulder, Kenneth R. Hess, Elliana Young, Vicente Valero, Lajos Pusztai, Beverly Carol Handy, Terrie G. Gornet, Nuhad K. Ibrahim, Daniel J. Booser
Publikováno v:
Breast Cancer Research and Treatment. 137:631-636
Bone is the most common site of metastasis of breast cancer, affecting most women with advanced disease. Procollagen type I N-terminal propeptide (P1NP), osteocalcin, CTX, and IL-6 are markers of bone turnover. Our objective was to determine whether
Autor:
Massimo Cristofanilli, D. Esseltine, Rabiul Islam, Kristine Broglio, Gabriel N. Hortobagyi, James Stec, A. M. Gonzalez-Angulo, JM Reuben, Lajos Pusztai, C. H. Yang, Daniel J. Booser, Savitri Krishnamurthy
Publikováno v:
Annals of Oncology. 17:813-817
2 Hematopathology, 3 Pathology, 5 Background: Bortezomib (VELCADE � ) is a potent inhibitor of the 26S proteasome with broad antitumor activity. We performed a phase II study of bortezomib to evaluate its clinical effects in patients with metastati
Autor:
Jie Willey, Ronald S. Walters, Daniel J. Booser, Vicente Valero, Richard L. Theriault, Gabriel N. Hortobagyi, Nuhad K. Ibrahim, Aman U. Buzdar
Publikováno v:
American Journal of Clinical Oncology: Cancer Clinical Trials. 23:117-121
The purpose of this study was to evaluate the maximum tolerated dose and the toxicity profile of vinorelbine administered by continuous infusion for 96 hours to patients who had received prior chemotherapy for metastatic breast cancer. Forty-three pa
Autor:
Angelica M. Gutierrez-Barrera, Jennifer K. Litton, Soley Bayraktar, Heather Lin, Gabriel N. Hortobagyi, V. Valero, Daniel J. Booser, Nisreen Elsayegh, Phuong Khanh Morrow, Marjorie C. Green, Nuhad K. Ibrahim, Tunc Tasbas, Banu Arun
The aim of this study was to compare the time-to progression and overall survival (OS) in patients with metastatic breast cancer (MBC) with and without deleterious BRCA1/2 mutations. 195 women with MBC who were referred for BRCA genetic testing betwe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f36283f6a5c91e3a3f95b2e456e24f4
https://europepmc.org/articles/PMC3857726/
https://europepmc.org/articles/PMC3857726/
Autor:
Paolo Morandi, Daniel J. Booser, Lajos Pusztai, Deborah Francis, Banu Arun, Rabiul Islam, Massimo Cristofanilli, B-N Lee, Savitri Krishnamurthy, Gabriel N. Hortobagyi, V. Valero, Marjorie C. Green, Adriana Lopez, JM Reuben
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 19(10)
Background: Novel molecular therapies for metastatic breast cancer (MBC) are necessary to improve the dismal prognosis of this condition. Imatinib mesylate (Gleevec®) inhibits several protein tyrosine kinases, including platelet-derived growth facto
Autor:
Ronald S. Walters, Frankie A. Holmes, Julian Rosenthal, Gabriel N. Hortobagyi, Debbie Frye, James A. Young, Kristine Broglio, Ana M. Gonzalez-Angulo, Shivaji Gunale, Kapil Dhingra, Daniel J. Booser, Garth Beinart
Publikováno v:
Cancer chemotherapy and pharmacology. 60(1)
This phase II trial was conducted to assess the efficacy and safety of 10-Ethyl-10-Deaza-Aminopterin (10-EDAM), a folate antagonist, in metastatic breast cancer patients who had received no more than one prior chemotherapy regimen. Fifty-five patient
Publikováno v:
Cancer. 103(9)
BACKGROUND Accurate assessment of HER-2 status is necessary prior to anti-HER-2 antibody (trastuzumab) therapy for metastatic breast carcinoma. However, controversy exists regarding whether to assess HER-2 status in the primary tumor or in metastatic
Autor:
Daniel J. Booser, Nuhad K. Ibrahim, Vicente Valero, Francisco J. Esteva, Windy Dean-Colomb, Gabriel N. Hortobagyi, Stacy L. Moulder, Kenneth R. Hess, Lajos Pusztai, Terrie G. Gornet, Elliana J. Young, Beverly Carol Handy
Publikováno v:
Journal of Clinical Oncology. 30:10613-10613
10613 Background: Bone is the preferred site for metastasis of breast cancer, affecting approximately 70% of women with advanced disease. N-terminal of procollagen type 1 (P1NP), c-terminal peptide crosslinks (CTX), Osteocalcin (OC) and interleukin-6
Autor:
Richard L. Theriault, Gabriel N. Hortobagyi, Daniel J. Booser, Frankie A. Holmes, Vicente Valero, Giuseppe Fraschini, Aman U. Buzdar, Kapil Dhingra, Lia Gutierrez
Publikováno v:
Investigational new drugs. 12(3)
We conducted a phase II trial of the novel immunomodulatory/cytotoxic agent 15-deoxyspergualin in patients with metastatic breast cancer who had failed treatment with front-line chemotherapy. Thirty-eight courses of treatment were administered to fou
Publikováno v:
Ophthalmology. 108:994-995
Objective To report a newly recognized side effect of a commonly used antineoplastic agent, docetaxel, in three patients with metastatic breast cancer. Design Observational case reports. Participants Three patients with metastatic breast cancer who r